Humanin Fragment Peptide HNF14 Shows Promise for Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, characterized by damage to the macula, a central part of the retina. It involves complex processes like oxidative stress, inflammation, and abnormal blood vessel growth (choroidal neovascularization). Current treatments for wet AMD are effective but invasive, and there are limited options for dry AMD, highlighting an urgent need for novel, less invasive therapeutic strategies that address the underlying pathology. This study specifically aimed to characterize the therapeutic potential of a humanin fragment peptide, HNF14, in an AMD model.

Treatment with HNF14 significantly mitigated key pathological features of AMD in the mouse model. The high-dose HNF14 group showed a 43% reduction in CNV lesion area compared to vehicle control (p<0.001), indicating potent anti-angiogenic effects. Furthermore, HNF14 treatment led to a 2.5-fold decrease in inflammatory cytokine expression (e.g., IL-6, TNF-α) in retinal tissue (p<0.01). The most significant finding was that HNF14 preserved retinal function, with ERG b-wave amplitudes in treated eyes being 35% higher than controls (p<0.005), suggesting neuroprotective benefits. Low-dose HNF14 also showed beneficial effects, albeit to a lesser extent, with a 28% reduction in CNV area (p<0.05). These findings suggest HNF14 acts through multiple pathways, including anti-angiogenic, anti-inflammatory, and neuroprotective mechanisms.